Marinella Clerico

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

The importance of maintaining effective therapy in multiple sclerosis.

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

Interferon-beta1a for the treatment of multiple sclerosis.

Adherence to interferon-beta treatment and results of therapy switching.

The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Risk factors for tumor occurrence in patients with myasthenia gravis.

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.

Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2.

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

Epigenetic therapy for Friedreich ataxia.

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.

Influence of cigarette smoking on ALS outcome: a population-based study.